MedX Health Announces a Pharmacy Pilot in Sweden and Distribution Agreement in Australia and New Zealand

“We are very pleased to be able to expand the distribution of our technology working with our trusted channel partner in Europe for pharmacy-based “on-demand” skin assessments. They have been successful in building a pharmacy-based cancer screening business to approximately 100 locations in Norway, and have opened 8 pilot locations in a pharmacy chain in Sweden, which has almost twice the population of Norway. One of the pharmacy-based model’s features is that MedX earns fee revenue per patient scanned, so this is an attractive market for us in Europe, as well as one we are pursuing in North America,” said Rob von der Porten, MedX CEO.

“Furthermore, the finalization of our distribution agreement for Australia and New Zealand with a leading medical distributor to physicians and clinics is a positive development for the Company, since this distributor is familiar with our SIAscopy technology. The recent the addition of New Zealand to the agreement increases the target market,” continued Mr. von der Porten.

Australia and New Zealand together have a population of almost 30 million. Australia has one of the highest rates of skin cancer, accounting for about 80% of all new cancers diagnosed there. Australians are 4 times more likely to develop a skin cancer than any other form of cancer; over 750,000 Australians are treated for skin cancer each year.

About MedX MedX, headquartered in Mississauga, Ontario, is a leading medical device company focused on skin cancer; it manufactures and distributes SIMSYS™ and MoleMate™, hand-held devices that use patented technology utilizing light and its remittance to view beneath suspicious moles and lesions in a pain free, non-invasive manner, creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. The devices are sold to physicians, clinics as well as being deployed in pharmacy settings where the images are sent remotely to dermatologists who perform a diagnosis. These products are Health Canada, FDA ARTG and CE approved and cleared for use in Canada, the US, Australia and Europe. MedX also designs, manufactures and distributes quality low level laser and light therapy technologies for use in numerous medical settings, approved in major jurisdictions, providing drug free and non-invasive treatment of tissue damage and pain. For more information and a complete profile of MedX and its products visit www.medxhealth.com.

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.